Form D · Pharmaceuticals
Lipidio Pharmaceuticals Inc.
San Diego, CA · CIK 0001794644
Offering snapshot reported Nov 21, 2019 · SEC filing
- Reported sold
- $4.62M Offering amount: $12M
- Investors reported
- 58 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 8, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 21, 2019 | Initial | $4,622,530 | No comparison | 58 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $462K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-353962
In addition to the Sale Commissions, a warrant to purchase 358,338 shares of the Issuer's common stock was issued.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Nov 21, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Bullough | Director |
| J. Gordon Foulkes | Director, Executive |
| Daniel Petree | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3570 Carmel Mountain Rd Ste 200
San Diego, CA, 92130
San Diego, CA, 92130